Rezolute (RZLT) Consolidated Net Income (2012 - 2026)
Rezolute recorded quarterly Consolidated Net Income of -$16.2 million in Q1 2026, up 28.99% quarter-over-quarter from -$22.8 million in Q4 2025, and up 14.48% year-over-year from -$14.1 million in Q1 2025.
Rezolute's Consolidated Net Income history runs 15 years deep, the most recent figure standing at -$16.2 million for Q1 2026.
- In Q1 2026, Consolidated Net Income rose 14.48% year-over-year to -$16.2 million; the TTM figure through Mar 2026 stood at -$81.5 million (down 13.07% YoY), while the FY2025 annual figure was -$74.4 million, down 13.51% from the prior year.
- Consolidated Net Income came in at -$16.2 million for Q1 2026 at Rezolute, up from -$22.8 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$9.8 million in Q3 2022 to a low of -$24.4 million in Q2 2025.
- A 5-year average of -$16.0 million and a median of -$15.4 million in 2024 frame the typical range for Consolidated Net Income.
- Across the five-year window, Consolidated Net Income tumbled 104.34% in 2022 and advanced 14.48% in 2026, its largest moves.
- Rezolute's Consolidated Net Income stood at -$13.5 million in 2022, then fell by 2.57% to -$13.9 million in 2023, then retreated by 13.28% to -$15.7 million in 2024, then tumbled by 44.73% to -$22.8 million in 2025, then climbed by 28.99% to -$16.2 million in 2026.
- According to Business Quant data, Consolidated Net Income over the past three periods registered -$16.2 million, -$22.8 million, and -$18.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | -16.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.17 Mn |
| Dec 31, 2025 | -22.77 Mn |
| Sep 30, 2025 | -18.14 Mn |
| Jun 30, 2025 | -24.41 Mn |
| Mar 31, 2025 | -18.91 Mn |
| Dec 31, 2024 | -15.74 Mn |
| Sep 30, 2024 | -15.36 Mn |
| Jun 30, 2024 | -22.06 Mn |
| Mar 31, 2024 | -15.09 Mn |
| Dec 31, 2023 | -13.89 Mn |
| Sep 30, 2023 | -14.51 Mn |
| Jun 30, 2023 | -12.76 Mn |
| Mar 31, 2023 | -15.66 Mn |
| Dec 31, 2022 | -13.54 Mn |
| Sep 30, 2022 | -9.82 Mn |
| Jun 30, 2022 | -11.23 Mn |
| Mar 31, 2022 | -11.20 Mn |
| Dec 31, 2021 | -12.59 Mn |
| Sep 30, 2021 | -8.08 Mn |
| Jun 30, 2021 | -6.64 Mn |
| Mar 31, 2021 | -5.48 Mn |
| Dec 31, 2020 | -7.10 Mn |
| Sep 30, 2020 | -3.62 Mn |
| Jun 30, 2020 | -3.55 Mn |
| Mar 31, 2020 | -5.04 Mn |
| Dec 31, 2019 | -6.67 Mn |
| Sep 30, 2019 | -5.08 Mn |
| Jun 30, 2019 | -7.83 Mn |
| Mar 31, 2019 | -22.93 Mn |
| Dec 31, 2018 | -4.16 Mn |
| Sep 30, 2018 | -3.37 Mn |
| Jun 30, 2018 | -11.95 Mn |
| Mar 31, 2018 | -5.01 Mn |
| Dec 31, 2017 | -5.75 Mn |
| Sep 30, 2017 | -6.72 Mn |
| Jun 30, 2017 | -6.22 Mn |
| Mar 31, 2017 | -5.39 Mn |
| Dec 31, 2016 | -4.89 Mn |
| Sep 30, 2016 | -3.83 Mn |
| Jun 30, 2016 | -3.87 Mn |
| Mar 31, 2016 | -3.72 Mn |
| Dec 31, 2015 | -4.07 Mn |
| Sep 30, 2015 | -3.30 Mn |
| Jun 30, 2015 | -3.09 Mn |
| Mar 31, 2015 | -2.30 Mn |
| Dec 31, 2014 | -3.07 Mn |
| Sep 30, 2014 | -2.23 Mn |
| Jun 30, 2014 | -2.23 Mn |
| Mar 31, 2014 | -5.03 Mn |
| Dec 31, 2013 | -1.27 Mn |
| Sep 30, 2013 | -862,266.00 |
| Jun 30, 2013 | -1.18 Mn |
| Mar 31, 2013 | -4.22 Mn |
| Dec 31, 2012 | -537,514.00 |
| Sep 30, 2012 | -630,850.00 |
| Jun 30, 2012 | -398,209.00 |
| Mar 31, 2012 | -176,870.00 |